Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Increased Fatty Acid Synthase is a Therapeutic Target in Mesothelioma
Ist Teil von
Clinical cancer research, 2001-01, Vol.7 (1), p.153-157
Ort / Verlag
Philadelphia, PA: American Association for Cancer Research
Erscheinungsjahr
2001
Quelle
MEDLINE
Beschreibungen/Notizen
Many common human cancer tissues express high levels of fatty acid
synthase (FAS), the primary enzyme for the synthesis of fatty acids,
and the differential expression of FAS between normal and neoplastic
tissues has led to the consideration of FAS as a target for anticancer
therapy. To investigate the potential of targeting FAS for the
treatment of pleural mesothelioma, we first determined whether FAS is
overexpressed in human mesothelioma. By immunohistochemistry, we found
22 of 30 human mesothelioma tissue samples tested to express
significantly increased levels of FAS compared with normal tissues,
including mesothelium. To further explore FAS as a therapeutic target
in mesothelioma, we established a nude mouse xenograft model for human
mesothelioma using the H-Meso cell line. The i.p. xenografts of this
cell line have high levels of FAS expression and fatty acid synthesis
pathway activity and grow along mesothelial surfaces in a manner
similar to the growth pattern of human mesothelioma. Growth of these
tumor xenografts was essentially abolished in mice treated with weekly
i.p. injections of C75, a synthetic, small molecule inhibitor of FAS,
at levels that resulted in no significant systemic toxicity except for
reversible weight loss. These results suggest that FAS may be an
effective target for pharmacological therapy in a high proportion of
human mesotheliomas.